OREANDA-NEWS A vaccine called CTH522 has been tested on 35 healthy female volunteers. It introduced two modifications of the drug, as well as a placebo. The vaccine entered the body intramuscularly and internally (through the nose) - at the beginning of the study, after a month, and then another four months later.

The vaccine is based on the protein of the outer membrane of the bacterium C. Trachomatis, which causes chlamydia. The first modification of the drug provided for enhanced cellular immunity, the second - increased antibody production. The second vaccine produced 5.6 times more antibodies - it will be most likely to be studied in subsequent studies.

Serious complications were not detected in any of the study participants. The most common side effect was pain at the injection site, as well as sneezing, nasal congestion and increased mucus production during the delivery of the vaccine internally.